VirTech Bio, Inc is a cutting-edge biotechnology company based in Natick, MA. They are at the forefront of developing the most advanced human-derived HBOC platform, known as OxyBridge, for the treatment of hemorrhagic shock and donor organ transplants. With a focus on addressing critical medical needs, VirTech Bio aims to provide life-saving solutions for trauma patients and improve the success rates of organ transplants.
Through their innovative technology, OxyBridge delivers critical oxygen and maintains blood pressure, making it a potential alternative or bridge to blood transfusion in emergency situations. The company also collaborates with a European organ perfusion device manufacturer to enhance organ transplantation outcomes. With strategic advantages in regulatory challenges and ease of manufacturing, VirTech Bio is poised to make a significant impact in the medical field when OxyBridge enters the market in early 2025.
Generated from the website